Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016', provides in depth analysis on Catenin Beta-1 (Beta Catenin or CTNNB1) targeted pipeline therapeutics. The report provides comprehensive information on the Catenin Beta-1 (Beta Catenin or CTNNB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Catenin Beta-1 (Beta Catenin or CTNNB1) - The report reviews Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects - The report assesses Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Catenin Beta-1 (Beta Catenin or CTNNB1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Catenin Beta-1 (Beta Catenin or CTNNB1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Catenin Beta-1 (Beta Catenin or CTNNB1) Overview 7 Therapeutics Development 8 Catenin Beta-1 (Beta Catenin or CTNNB1) - Products under Development by Stage of Development 8 Catenin Beta-1 (Beta Catenin or CTNNB1) - Products under Development by Therapy Area 9 Catenin Beta-1 (Beta Catenin or CTNNB1) - Products under Development by Indication 10 Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Catenin Beta-1 (Beta Catenin or CTNNB1) - Products under Development by Companies 13 Catenin Beta-1 (Beta Catenin or CTNNB1) - Products under Development by Universities/Institutes 15 Catenin Beta-1 (Beta Catenin or CTNNB1) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Catenin Beta-1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development 24 Dicerna Pharmaceuticals, Inc. 24 iBeCa Therapeutics 25 Marina Biotech, Inc. 26 Propanc Health Group Corporation 27 ScarX Therapeutics 28 Warp Drive Bio, Inc. 29 Catenin Beta-1 (Beta Catenin or CTNNB1) - Drug Profiles 30 Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 CEQ-508 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 exisulind - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 nefopam hydrochloride - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 PRP - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules for Inflammation - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecules to Inhibit Beta-Catenin for Oncology - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Catenin Beta-1 (Beta Catenin or CTNNB1) - Dormant Projects 44 Catenin Beta-1 (Beta Catenin or CTNNB1) - Featured News & Press Releases 45 Apr 19, 2016: Propanc Files Two More Patents Citing New Compositions of Proenzymes for Cancer Treatment 45 Mar 02, 2016: Propanc Confirms PRP Response to Broad Range of Cancer Indications; Sets Date for Scientific Advice Meeting with UK Regulators 45 Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics 47 Feb 04, 2016: Propanc Discovers PRP Dramatically Suppresses Cancer Stem Cells 47 Nov 17, 2015: Propanc Demonstrates Significant Anti-Tumor Efficacy in Pancreatic and Ovarian Cancer Preclinical Models; Files Patent Specifying New Therapeutic Target Dose Range 49 Aug 31, 2015: Propanc Receives Patent Approval in Key Jurisdiction 50 Aug 05, 2015: Marina Biotech's CEQ508 Granted FDA Fast Track Designation for Familial Adenomatous Polyposis 50 Jul 09, 2015: Propanc Identifies Positive Signals for Efficacy from Pilot Animal Studies 51 May 06, 2015: Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non-human Primates with DsiRNA-EX Conjugates Being Investigated for Treatment of Primary Hyperoxaluria Type 1 (PH1) 52 May 04, 2015: Dicerna to Present at the 17th Annual TIDES: Oligonucleotide and Peptide Therapeutics From Research through Commercialization Conference 53 Apr 10, 2015: Dicerna Presents New -catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting at Cold Spring Harbor Laboratory 53 Apr 03, 2012: Marina Biotech Completes Dosing Of Second Cohort In Phase Ib START-FAP Clinical Trial Of CEQ508 54 Feb 29, 2012: Marina Biotech Presents Advances In Oral Delivery Of Nucleic Acids At AsiaTIDES Conference In Tokyo 55 Jan 25, 2012: Marina Biotech Starts Cohort 2 Of Phase Ib START-FAP Clinical Trial Of CEQ508 55 Jun 09, 2011: Marina Biotech Completes Dosing Of First Cohort In Phase Ib/IIa START-FAP Clinical Trial Of CEQ508 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 24 Pipeline by iBeCa Therapeutics, H1 2016 25 Pipeline by Marina Biotech, Inc., H1 2016 26 Pipeline by Propanc Health Group Corporation, H1 2016 27 Pipeline by ScarX Therapeutics, H1 2016 28 Pipeline by Warp Drive Bio, Inc., H1 2016 29 Dormant Projects, H1 2016 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
